Form 8-K Cryomass Technologies, For: Aug 09
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer | ||
| incorporation) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area
code
(Andina Gold Corp.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of each Exchange on which Registered | ||
| None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On August 9, 2022, Cryomass Technologies Inc (OTCQX: CRYM) (the “Company”) issued a press release, a copy of which is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
The information in Item 7.01 of this Current Report and Exhibit 99.1 is being furnished, not filed, pursuant to Items 7.01 and 9.01 of Form 8-K. Accordingly, the information in Items 7.01 and 9.01 of this Current Report, including Exhibit 99.1, will not be subject to liability under Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and will not be incorporated by reference into any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference. The furnishing of information in this Current Report, including Exhibit 99.1, is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report, including Exhibit 99.1, is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.
Item 9.01. Financial Statements and Exhibits.
| EXHIBIT 99.1 | Cryomass Technologies Inc Press Release August 9, 2022 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
NOTE REGARDING FORWARD LOOKING STATEMENTS
Any statements in this Current Report on Form 8-K or any exhibit hereto about future expectations, plans, and prospects for the Company, including statements about Company’s future expectations, beliefs, goals, plans, or prospects, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. In some cases you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “likely,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms.
These forward-looking statements involve risks, uncertainties, and assumptions that could cause actual performance or results to differ materially from those expressed or suggested by the forward-looking statements. If any of these risks or uncertainties materialize, or if any of Company’s assumptions prove incorrect, its actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include risks associated with: Company’s ability to achieve or maintain profitability, and to effectively manage its anticipated growth; and the risks described in the other filings Company makes with the Securities and Exchange Commission from time to time, including the risks described under the heading “Risk Factors” in Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent quarterly reports on Form 10-Q, and which should be read in conjunction with its financial results and forward-looking statements. All forward-looking statements in this Current Report on Form 8-K or any exhibit hereto are based on information available to Company as of the date hereof, and it does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cryomass Technologies Inc
| /s/ Christian Noël | |
| Christian Noël | |
| CEO | |
| Date: August 9, 2022 |
Exhibit 99.1
CryoMass Technologies Appoints Top Extractor Sales Veteran To Lead Global Sales Just Ahead Of California Product Launch
NEWS PROVIDED BY
CryoMass Technologies Inc
Aug 09, 2022, 07:11 ET
Mike Stringile Named International Sales Director
DENVER, Aug. 9, 2022 /PRNewswire/ -- CryoMass Technologies Inc. (the "Company" or "CryoMass") (OTCQX: CRYM) welcomes Mike Stringile to lead its worldwide sales team as it prepares to launch its first commercial installation next month in Monterey, California. Mr. Stringile brings unsurpassed cannabis industry extraction knowledge and sales experience to CryoMass.
Mike began his extraction career working in the oil and gas industry in Fort McMurray, Alberta,
where he was immersed in the complex world of extracting hydrocarbons from oil sands. After spending more than seven years honing his technical knowledge of hydrocarbon extraction processes, Mike was given the opportunity to apply his extraction expertise to the burgeoning new cannabis industry.
In November 2018, Mr. Stringile joined an upstart C02 extraction company based in Kelowna, British Columbia, called Vitalis Extraction Technologies. It didn't take long for Mike's expertise to pay off. Mike integrated his oil and gas industry knowledge into the design of their extractors, which resulted in the development of industry-leading C02 extractors for the cannabis industry. Simultaneously Mike built an ancillary sales department that did much more than sell extractors; it sold much-needed extraction knowledge and process integration expertise to cannabis companies. In the first 18 months, Mike's sales division generated more than $18 million in revenues for Vitalis.
Then in March 2020, during the Covid lockdowns, Mr. Stringile co-founded AGMS Solutions Inc., which continues to provide a comprehensive suite of extraction-oriented consulting services to the cannabis industry. AGMS quickly developed a worldwide network of cannabis cultivators, extractors, and finished goods producers seeking to avail themselves of advanced and customized extraction solutions.
CryoMass Director and CEO Christian Noël stated, "Having someone with both the technical extraction expertise and proven sales experience that Mr. Stringile possesses is extremely rare in today's cannabis industry. I am extremely confident that between Mike and our current Director of U.S. Sales, Steve Cimini, we have the perfect team to rapidly build an international sales and toll-partnering network that generates millions of dollars of revenues."
Mr. Stringile, commenting on his appointment, stated, "I am extremely excited about the opportunity to lead the development and deployment of a robust international sales effort for CryoMass. I've seen just about everything there is to see when it comes to extraction technologies and when I understood what these guys were up to, I immediately thought of just one thing… this will change everything. And the beauty of this must-have technology is that it is patent-protected until 2038. I see this as a major game changer for the entire industry – globally."
The common stock of CryoMass Technologies Inc. trades on the OTC QX market under the symbol CRYM. For further information, please contact the Company by email at [email protected] or by telephone at +1 833 256 2382.
This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.
Forward-looking Statements
This press release may contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that involve known and unknown risks, uncertainties and other factors, including risk factors identified in the Company's SEC filings, and which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, changes in the regulatory environment affecting the sale and use of cannabis or hemp products and of other, potential lines of businesses that the Company will consider entering at a given time, demand for the Company's products, internal funding and the financial condition of the Company, product roll-out, competition, our dependence upon our commercial partners, variations in the global commodities markets and other commercial matters involving the Company, its products and the markets in which the Company operates or seeks to enter, as well as general economic conditions. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Marijuana, as defined in the U.S. Controlled Substances Act, remains a Schedule I drug under the respective act, making it illegal under federal law in the U.S. to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis- related business activities in the U.S. may form the basis for prosecution under applicable U.S. federal money laundering legislation. Please carefully review the Company's SEC filings with respect to related risk factor.
SOURCE CryoMass Technologies Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nationwide Insurance to Showcase How they are Driving Proactive Risk Management Using iLearningEngines’ Enterprise AI Platform at the 2024 Insurance Innovators Conference
- Ecopetrol files its 20-F Annual Report before the Securities and Exchange Commission
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
